Clinical Scorecard: Faricimab Maintains Long-Term Stability in Diabetic Macular Edema (DME)
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | Faricimab targets angiopoietin-2 and VEGF pathways to reduce retinal edema and improve visual acuity. |
| Target Population | Patients with diabetic macular edema, including those previously treated with aflibercept or faricimab. |
| Care Setting | Ophthalmology clinical settings specializing in retinal diseases. |
Key Highlights
- Over 50% of patients on faricimab treat-and-extend achieved dosing intervals up to 20 weeks after 4 years.
- Sustained improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST) maintained through 4 years.
- Patients switching from aflibercept to faricimab showed further reduction in hard exudates, a marker of severe DME.
Guideline-Based Recommendations
Diagnosis
- Confirm diagnosis of diabetic macular edema with clinical examination and imaging including OCT.
Management
- Consider faricimab treat-and-extend dosing for long-term management of DME.
- Switch patients inadequately controlled on aflibercept to faricimab to potentially improve anatomical outcomes.
Monitoring & Follow-up
- Regular assessment of BCVA and CST to evaluate treatment efficacy and guide dosing intervals.
- Monitor for resolution of hard exudates as a marker of disease severity improvement.
Risks
- Faricimab demonstrated a safety profile consistent with prior studies YOSEMITE and RHINE, with good tolerability over 4 years.
Patient & Prescribing Data
DME patients previously treated with faricimab or aflibercept in clinical trials.
Long-term faricimab use via treat-and-extend regimen maintains visual and anatomical stability with extended dosing intervals, reducing injection burden.
Clinical Best Practices
- Initiate faricimab treatment early to achieve faster CST reduction with fewer injections.
- Use treat-and-extend dosing to personalize injection intervals up to 20 weeks based on patient response.
- Consider switching from aflibercept to faricimab in patients with persistent hard exudates or suboptimal response.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
